Rob Stein

Rob Stein is a correspondent and senior editor on NPR's science desk.

An award-winning science journalist with more than 30 years of experience, Stein mostly covers health and medicine. He tends to focus on stories that illustrate the intersection of science, health, politics, social trends, ethics, and federal science policy. He tracks genetics, stem cells, cancer research, women's health issues, and other science, medical, and health policy news.

Before NPR, Stein worked at The Washington Post for 16 years, first as the newspaper's science editor and then as a national health reporter. Earlier in his career, Stein spent about four years as an editor at NPR's science desk. Before that, he was a science reporter for United Press International (UPI) in Boston and the science editor of the international wire service in Washington.

Stein's work has been honored by many organizations, including the National Academy of Sciences, the American Association for the Advancement of Science, the American Association for Cancer Research, and the Association of Health Care Journalists. He was twice part of NPR teams that won Peabody Awards.

Stein frequently represents NPR, speaking at universities, international meetings and other venues, including the University of Cambridge in Britain, the World Conference of Science Journalists in South Korea, and the Aspen Institute in Washington, DC.

Stein is a graduate of the University of Massachusetts, Amherst. He completed a journalism fellowship at the Harvard School of Public Health, a program in science and religion at the University of Cambridge, and a summer science writer's workshop at the Marine Biological Laboratory in Woods Hole, Mass.

Updated at 11:50 a.m. ET

Federal health officials say they have resolved a problem that has hindered wide testing for the new coronavirus in the United States, a crucial practice for fighting the spread of the dangerous new infection.

A problem with one ingredient in test kits that the federal Centers for Disease Control and Prevention distributed to labs around the country had created a frustrating bottleneck in testing, requiring most testing to occur at the CDC in Atlanta.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

DAVID GREENE, HOST:

President Trump, at a press conference last night, chose the person who will lead the government's response to the coronavirus.

(SOUNDBITE OF PRESS CONFERENCE)

Chunlin Leonhard spends most of her time alone in her room at a hotel at the Travis Air Force Base in California, anxiously reading the latest news about the coronavirus outbreak in China.

"I'm doing about as well as can be hoped for under the circumstances," Leonhard, 55, a New Orleans law professor, says during an interview over Skype.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

MARY LOUISE KELLY, HOST:

The Trump administration's aggressive efforts to protect Americans from the coronavirus are drawing both praise and criticism.

On Friday, the federal government temporarily banned entry into the United States for anyone traveling from China who isn't a U.S. citizen, permanent resident or an immediate family member of either.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

AILSA CHANG, HOST:

Copyright 2020 NPR. To see more, visit https://www.npr.org.

RACHEL MARTIN, HOST:

Copyright 2019 NPR. To see more, visit https://www.npr.org.

MARY LOUISE KELLY, HOST:

Doctors are reporting the first evidence that genetically edited cells could offer a safe way to treat sickle cell disease, a devastating, incurable disorder that afflicts millions of people around the world.

Billions of cells that were genetically modified with the powerful gene-editing technique called CRISPR have started working, as doctors had hoped, inside the body of the first sickle cell patient to receive the experimental treatment, according to highly anticipated data released Tuesday.

Victoria Gray slides open a closet door, pulls out a suitcase and starts packing piles of clothes.

"My goodness," says Gray. "Did I really bring all this?"

Gray, who has sickle cell disease, is the first patient with a genetic disorder whom doctors in the United States have tried to treat using the powerful gene-editing technique CRISPR.

Pages